DULUTH, Ga., Dec. 30 /PRNewswire/ -- Merial, a world leading animal health company, and the Australian company Imugene have signed a comprehensive agreement allowing Merial to obtain exclusive rights to Imugene vector technology. Under the Strategic Alliance, Merial will progress candidates through the product development process to global sales. Additional vaccine candidates will be evaluated for proof of concept and, if successful, will also progress into the product development process.
The Strategic Alliance commences December 31st, 2008. Imugene has received an initial payment for future research and the reimbursement of past research fees.
The terms of the Strategic Alliance include the Poultry Productivity Enhancer previously sublicensed to Merial. This vaccine candidate will now be progressed with other FAV (Fowl Adeno Virus) and PAV (Porcine Adeno Virus) vectored vaccine candidates already researched by Imugene and additional vaccine candidates to be disclosed by Merial.
Commenting on the successful conclusion of the exclusive strategic alliance negotiations, Imugene Managing Director Dr. Warwick Lamb said, "The results from our recent trials and vaccine development activities have been significant and have led to the alliance arrangements with one of the world's leading animal health companies. Merial and Imugene will now collaborate over the coming years to develop of a suite of vaccines for worldwide sales."
"We are very pleased to enter this new phase of our relationship with
Imugene," said Bob Nordgren, Global Head of Merial Biologicals. "This
exclusive strategic alliance and licensing agreement gives Merial access to
important technology for our innovation of new approaches that could allow our
veterinarian customers innovative means for managing important, poorly
controlled diseases of swine and poultry. Our relationship dates back to the
very beginning of I
Copyright©2008 PR Newswire.
All rights reserved